On October 31, 2023 Asgard Therapeutics, a private biotech company pioneering in-vivo direct reprogramming for cancer immunotherapy, reported the presentation of a poster showcasing positive in vivo data (Press release, Asgard Therapeutics, OCT 31, 2023, View Source [SID1234636516]). These data will be presented at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper), which will take place in San Diego, California November 1-5, 2023.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The poster will showcase data supporting the effectiveness of AT-108, a novel off-the-shelf cancer immunotherapy based on an adenoviral vector encoding a proprietary combination of reprogramming factors, across immune checkpoint inhibitor-resistant tumors with different types of tumor microenvironment. The study’s results highlight the power of AT-108 to induce complete tumor regressions of non-immunogenic tumors, long-term systemic memory and protection against metastatic challenge.
"We are paving the way for the next generation of immune cell therapies bypassing the traditional hurdles of ex-vivo cell manipulation and immunogenic (neo)antigen identification," said Dr. Fabio Rosa, Co-Founder and Head of Research at Asgard Therapeutics. "Our in vivo data showcases the unique potential of in vivo direct cell reprogramming in cancer immunotherapy and lays the foundation for the ongoing pre-clinical development of AT-108 and its promising path toward IND submission and clinical trials."
The full abstract is available at Journal for ImmunoTherapy of Cancer, and details of the poster presentation are as follows:
SITC poster
Title: In-situ reprograming of cancer cells to cDC1s elicits complete tumor regression and immune memory as monotherapy
Time: Saturday, Nov 4, 9 am – 8:30 pm
Presenter: Xiaoli Huang, PhD, Project Director Preclinical Pharmacology
Abstract Number: 1204